therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2024-5-2-38-47therapeutic-427Research ArticleОБЗОРЫREVIEWSКлинико-экономические исследования фармакотерапии множественной миеломы: данные литературного обзораClinical and economic studies of pharmacotherapy for multiple myeloma: literature review datahttps://orcid.org/0000-0001-6304-4594ЛучининЕ. А.LuchininE. A.

Лучинин Евгений Алексеевич - преподаватель кафедры профпатологии, гематологии и клинической фармакологии, Scopus Autor ID: 57220079650.

Саратов

Evgeny A. Luchinin - Lecturer at the Department of Occupational Pathology, Hematology and Clinical Pharmacology, Scopus Author ID: 57220079650.

Saratov

Luchinin.gly10@gmail.comhttps://orcid.org/0000-0002-9198-8661ЖуравлеваМ. В.ZhuravlevaM. V.

Журавлева Марина Владимировна - д.м.н., профессор, зам. директора Центра клинической фармакологии ФГБУ Научный центр экспертизы средств медицинского применения МР; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет).

Москва

Marina V. Zhuravleva - Doctor of Medical Sciences, Professor; Deputy Director of the Center for Clinical Pharmacology Federal State Budgetary Institution Scientific Center for Expertise of Medicinal Products M HRF; Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, First MSMU named after I.M. Sechenov of the MH RF (Sechenov University).

Moscow

mvzhuravleva@mail.ruhttps://orcid.org/0000-0002-4737-7695ШелеховаТ. В.ShelehovaT. V.

Шелехова Татьяна Владимировна - д.м.н., профессор, заведующая кафедрой профпатологии, гематологии и клинической фармакологии.

Саратов

Tatiana V. Shelekhova - Dr. Sci. (Med.), professor, Head of the Department of Occupational Pathology, Hematology and Clinical Pharmacology.

Saratov

tshelexova@mail.ruhttps://orcid.org/0000-0002-6758-2389КокушкинК. А.KokushkinK. A.

Кокушкин Константин Александрович - научный руководитель.

Москва

Konstantin A. Kokushkin - research supervisor State Budgetary Institution of the Moscow region «Clinical and Economic.

Moscow

kokushkinka@gmail.comhttps://orcid.org/0000-0002-3120-8491ЛучининаЕ. В.LuchininaE. V.

Лучинина Елена Валентиновна - к.м.н., доцент кафедры профпатологии, гематологии и клинической фармакологии, начальник отдела контроля за обращением лекарственных средств и медицинских изделий клинического центра, Researcher ID: AAD-4774-2021, eLIBRARY SPIN-код: 9505-5244, Scopus Author ID: 57217133083.

Саратов

Elena V. Luchinina - PhD, Associate Professor of the Department of Occupational Pathology, Hematology and Clinical Pharmacology; Researcher ID: AAD-4774-2021, eLIBRARY SPIN-код: 9505-5244, Scopus Author ID: 57217133083.

Saratov

eluchinina16@mail.ruФГБОУ ВО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава РоссииРоссияSaratov State Medical University n.a. V.I. Razumovsky of the Ministry of Health of RussiaRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России (Сеченовский Университет); ФГБУ «Научный центр экспертизы средств медицинского применения» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University); Center for Clinical Pharmacology Federal State Budgetary Institution Scientific Center for Expertise of Medicinal Products of the Ministry of Health of the Russian FederationRussian FederationГБУ МО «Научно-практический центр клинико-экономического анализа Министерства здравоохранения Московской области»РоссияResearch supervisor State Budgetary Institution of the Moscow region «Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry»Russian Federation202424062024523847Copyright © Лучинин Е.А., Журавлева М.В., Шелехова Т.В., Кокушкин К.А., Лучинина Е.В., 20242024Лучинин Е.А., Журавлева М.В., Шелехова Т.В., Кокушкин К.А., Лучинина Е.В.Luchinin E.A., Zhuravleva M.V., Shelehova T.V., Kokushkin K.A., Luchinina E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/427

Среди гематологических заболеваний Множественная миелома (ММ) является вторым наиболее распространённым злокачественным новообразованием у взрослых во всём мире. В подавляющем большинстве случаев ММ остается неизлечимой, несмотря на повышение выживаемости без прогрессирования и общей выживаемости на фоне успехов в фармакотерапии, а также появления в последние годы инновационных препаратов. К сожалению, это не спасает пациентов от рецидива, невосприимчивости ко многим препаратам и неблагоприятного прогноза. В условиях ограниченного финансирования одним из определяющих факторов успеха терапии является стоимость лечения. Возникает необходимость проведения клинико-экономического анализа применения таргетных лекарственных препаратов для определения наиболее экономически оправданного варианта лечения.

Цель обзора — дать представление о применяющихся в настоящее время, а также экспериментальных методах лечения рецидивирующей/рефрактерной ММ (РРMM) с акцентом на их фармакоэкономическую доступность, чтобы облегчить врачам процесс принятия решений. Представлены самые последние данные, которые помогут усовершенствовать подходы к лечению этого всё ещё неизлечимого заболевания, и анализ фармакоэкономических исследований современных дорогостоящих схем лечения РРММ в различных странах.

Among hematological diseases, Multiple myeloma (MM) is the second most common malignancy in adults worldwide. In the vast majority of cases, MM remains incurable, despite improvements in progression-free survival and overall survival due to advances in pharmacotherapy, as well as the emergence of innovative drugs in recent years. Unfortunately, this does not prevent patients from relapse and, ultimately, multidrug resistance and poor prognosis. In conditions of limited funding, one of the determining factors for the success of therapy is the cost of treatment. There is a need to conduct a clinical and economic analysis of the use of targeted drugs to determine the most economically feasible treatment option. The purpose of the review is to provide an overview of current and experimental treatments for relapsed/refractory MM (RRMM), with an emphasis on their pharmacoeconomic availability to assist clinicians in their decision-making process. Let's look at the latest data that will help improve approaches to the treatment of this still incurable disease and analyze pharmacoeconomic studies of modern expensive treatment regimens for RRMM in various countries.

множественная миеломафармакоэкономикафармакоэкономические исследования миеломы«затраты-эффективность»клинико-экономические исследованияоценка медицинских технологийmultiple myelomapharmacoeconomicspharmacoeconomic studies of myelomacost-effectiveness analysisclinical and economic studieshealth technology assessmentИсследование не имело спонсорской поддержкиReferencesOrlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019;19(8):522-530.e1. DOI: 10.1016/j.clml.2019.04.018Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clin Lymphoma Myeloma Leuk. 2019;19(8):522-530.e1. DOI: 10.1016/j.clml.2019.04.018Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186-197. Erratum in: Lancet. 2020;396(10249):466. DOI: 10.1016/S0140-6736(20)30734-0.Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186-197. Erratum in: Lancet. 2020;396(10249):466. DOI: 10.1016/S0140-6736(20)30734-0.Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021;39(22):2430-2442. DOI: 10.1200/JCO.21.00972Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021;39(22):2430-2442. DOI: 10.1200/JCO.21.00972Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875-1884. DOI: 10.1038/s41375-020-0711-6Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875-1884. DOI: 10.1038/s41375-020-0711-6Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124(20):4032-4043. DOI: 10.1002/cncr.31680Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124(20):4032-4043. DOI: 10.1002/cncr.31680Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1):3. DOI: 10.3390/medsci9010003Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1):3. DOI: 10.3390/medsci9010003Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data. Leuk Lymphoma. 2021;62(2):377-386. DOI: 10.1080/10428194.2020.1827253Braunlin M, Belani R, Buchanan J, Wheeling T, Kim C. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data. Leuk Lymphoma. 2021;62(2):377-386. DOI: 10.1080/10428194.2020.1827253van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018;9:2134. DOI: 10.3389/fimmu.2018.02134van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018;9:2134. DOI: 10.3389/fimmu.2018.02134Wang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):55. DOI: 10.1186/s13045-016-0284-zWang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):55. DOI: 10.1186/s13045-016-0284-zAsrar MM, Lad DP, Prinja S, Bansal D. A systematic review of economic evaluations of treatment regimens in multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):799-809. DOI: 10.1080/14737167.2020.1779064Asrar MM, Lad DP, Prinja S, Bansal D. A systematic review of economic evaluations of treatment regimens in multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):799-809. DOI: 10.1080/14737167.2020.1779064Fu S, Wu CF, Wang M, Lairson DR. Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review. Pharmacoeconomics. 2019;37(12):1421-1449. DOI: 10.1007/s40273-019-00828-yFu S, Wu CF, Wang M, Lairson DR. Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review. Pharmacoeconomics. 2019;37(12):1421-1449. DOI: 10.1007/s40273-019-00828-yAguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? J Clin Pharm Ther. 2016;41(2):189-197. DOI: 10.1111/jcpt.12384Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? J Clin Pharm Ther. 2016;41(2):189-197. DOI: 10.1111/jcpt.12384Picot J, Cooper K, Bryant J, Clegg AJ. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess. 2011;15(41):1-204. DOI: 10.3310/hta15410Picot J, Cooper K, Bryant J, Clegg AJ. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess. 2011;15(41):1-204. DOI: 10.3310/hta15410Gaultney JG, Redekop WK, Sonneveld P, Uyl-de Groot CA. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer. 2011;47(10):1458-1467. DOI: 10.1016/j.ejca.2011.04.005Gaultney JG, Redekop WK, Sonneveld P, Uyl-de Groot CA. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer. 2011;47(10):1458-1467. DOI: 10.1016/j.ejca.2011.04.005Richard S, Jagannath S, Cho HJ, Parekh S, Madduri D, et al. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Rev Hematol. 2021;14(1):31-45. DOI: 10.1080/17474086.2021.1858790Richard S, Jagannath S, Cho HJ, Parekh S, Madduri D, et al. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Rev Hematol. 2021;14(1):31-45. DOI: 10.1080/17474086.2021.1858790Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066-1077. DOI: 10.1038/s41375-021-01488-8Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066-1077. DOI: 10.1038/s41375-021-01488-8Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65-76. DOI: 10.1016/S1470-2045(21)00579-9Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65-76. DOI: 10.1016/S1470-2045(21)00579-9Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41(8):1600-1609. DOI: 10.1200/JCO.21.02734Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41(8):1600-1609. DOI: 10.1200/JCO.21.02734Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41(8):1590-1599. DOI: 10.1200/JCO.22.00940Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41(8):1590-1599. DOI: 10.1200/JCO.22.00940Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol. 2018; 125:1-11. DOI: 10.1016/j.critrevonc.2018.02.008Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol. 2018; 125:1-11. DOI: 10.1016/j.critrevonc.2018.02.008Armoiry X, Connock M, Tsertsvadze A, Cummins E, Melendez-Torres GJ, et al. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. Pharmacoeconomics. 2018;36(9):1073-1081. DOI: 10.1007/s40273-018-0644-3Armoiry X, Connock M, Tsertsvadze A, Cummins E, Melendez-Torres GJ, et al. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. Pharmacoeconomics. 2018;36(9):1073-1081. DOI: 10.1007/s40273-018-0644-3Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. DOI: 10.1038/s41408-020-00357-4Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. DOI: 10.1038/s41408-020-00357-4Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, et al. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Adv Ther. 2022;39(5):1976-1992. Erratum in: Adv Ther. 2022;39(8):3868-3869. DOI: 10.1007/s12325-022-02083-8Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, et al. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Adv Ther. 2022;39(5):1976-1992. Erratum in: Adv Ther. 2022;39(8):3868-3869. DOI: 10.1007/s12325-022-02083-8Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801-812. DOI: 10.1016/S1470-2045(21)00128-5Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801-812. DOI: 10.1016/S1470-2045(21)00128-5Ахмедов М.И., Зейналова П.А. Обзор экспертного совета «Множественная миелома». Онкогематология. 2023;18(2):10-16. DOI: 10.17650/1818-8346-2023-18-2-10-16Akhmedov M.I., Zeynalova P.A. Expert Council Review “Multiple myeloma”. Oncohematology. 2023;18(2):10-16. (In Russ.) DOI: 10.17650/1818-8346-2023-18-2-10-16Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, et al. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 2019;8(12):1522. DOI: 10.3390/cells8121522Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, et al. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 2019;8(12):1522. DOI: 10.3390/cells8121522Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. DOI: 10.1016/S0140-6736(21)00592-4Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. DOI: 10.1016/S0140-6736(21)00592-4Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107. Erratum in: Lancet. 2019;394(10214):2072. DOI: 10.1016/S0140-6736(19)32556-5Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107. Erratum in: Lancet. 2019;394(10214):2072. DOI: 10.1016/S0140-6736(19)32556-5Huang SX, Luo PH, Wang HL, Mo DC, Huang JF. Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma. J Clin Oncol. 2023;41(14):2667-2668. DOI: 10.1200/JCO.22.02665Huang SX, Luo PH, Wang HL, Mo DC, Huang JF. Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma. J Clin Oncol. 2023;41(14):2667-2668. DOI: 10.1200/JCO.22.02665Patel AP. Use of Daratumumab in Patients With Previously Treated Multiple Myeloma. J Clin Oncol. 2023;41(14):2668. DOI: 10.1200/JCO.22.02850Patel AP. Use of Daratumumab in Patients With Previously Treated Multiple Myeloma. J Clin Oncol. 2023;41(14):2668. DOI: 10.1200/JCO.22.02850Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726-1737. DOI: 10.1056/NEJMoa1817226Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726-1737. DOI: 10.1056/NEJMoa1817226Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. Erratum in: Lancet. 2021;398(10307):1216. DOI: 10.1016/S0140-6736(21)00933-8Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. Erratum in: Lancet. 2021;398(10307):1216. DOI: 10.1016/S0140-6736(21)00933-8Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10(2):17. DOI: 10.1038/s41408-020-0273-xDimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10(2):17. DOI: 10.1038/s41408-020-0273-xJackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73. DOI: 10.1016/S1470-2045(18)30687-9Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73. DOI: 10.1016/S1470-2045(18)30687-9Choon-Quinones M, Zelei T, Németh B, Tóth M, Jia XY, et al. Systematic literature review of health economic models developed for multiple myeloma to support future analyses. J Med Econ. 2023;26(1):110-119. DOI: 10.1080/13696998.2022.2144056Choon-Quinones M, Zelei T, Németh B, Tóth M, Jia XY, et al. Systematic literature review of health economic models developed for multiple myeloma to support future analyses. J Med Econ. 2023;26(1):110-119. DOI: 10.1080/13696998.2022.2144056Seefat MR, Cucchi DGJ, Dirven S, Groen K, Zweegman S, Blommestein HM. A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. Cancers (Basel). 2021;13(22):5606. DOI: 10.3390/cancers13225606Seefat MR, Cucchi DGJ, Dirven S, Groen K, Zweegman S, Blommestein HM. A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. Cancers (Basel). 2021;13(22):5606. DOI: 10.3390/cancers13225606GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1135-1159. DOI: 10.1016/S0140-6736(20)31404-5GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1135-1159. DOI: 10.1016/S0140-6736(20)31404-5Neves M, Trigo F, Rui B, João C, Lúcio P, et al. Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness. Pharmacoeconomics. 2021;39(5):579-587. DOI: 10.1007/s40273-020-00993-5Neves M, Trigo F, Rui B, João C, Lúcio P, et al. Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness. Pharmacoeconomics. 2021;39(5):579-587. DOI: 10.1007/s40273-020-00993-5Gong CL, Studdert AL, Liedtke M. Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis. Am J Hematol. 2019;94(3):E68-E70. DOI: 10.1002/ajh.25372Gong CL, Studdert AL, Liedtke M. Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis. Am J Hematol. 2019;94(3):E68-E70. DOI: 10.1002/ajh.25372Blommestein HM, Franken MG, van Beurden-Tan CHY, Blijlevens NMA, Huijgens PC, et al. Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. JAMA Netw Open. 2021;4(3):e213497. DOI: 10.1001/jamanetworkopen.2021.3497Blommestein HM, Franken MG, van Beurden-Tan CHY, Blijlevens NMA, Huijgens PC, et al. Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. JAMA Netw Open. 2021;4(3):e213497. DOI: 10.1001/jamanetworkopen.2021.3497Narsipur N, Bulla S, Yoo C, Do B, Tran K, et al. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021;27(12):1691-1702. DOI: 10.18553/jmcp.2021.27.12.1691Narsipur N, Bulla S, Yoo C, Do B, Tran K, et al. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021;27(12):1691-1702. DOI: 10.18553/jmcp.2021.27.12.1691Zeng X, Peng L, Peng Y, Tan C, Wan X. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. Clin Ther. 2020;42(2):251-262.e5. DOI: 10.1016/j.clinthera.2019.12.007Zeng X, Peng L, Peng Y, Tan C, Wan X. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. Clin Ther. 2020;42(2):251-262.e5. DOI: 10.1016/j.clinthera.2019.12.007Dolph M, Tremblay G, Leong H. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial. Pharmacoeconomics. 2021;39(11):1309-1325. DOI: 10.1007/s40273-021-01068-9Dolph M, Tremblay G, Leong H. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial. Pharmacoeconomics. 2021;39(11):1309-1325. DOI: 10.1007/s40273-021-01068-9Wu W, Ding S, Mingming Z, Yuping Z, Sun X, et al. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. J Med Econ. 2023;26(1):701-709. DOI: 10.1080/13696998.2023.2207742Wu W, Ding S, Mingming Z, Yuping Z, Sun X, et al. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. J Med Econ. 2023;26(1):701-709. DOI: 10.1080/13696998.2023.2207742Клабукова Д.Л., Крысанова В.С., Полякова К.И., Ермолаева Т.Н., Давыдовская М.В., Кокушкин К.А. Экономическое влияние применения трехкомпонентных схем с иксазомибом или карфилзомибом для терапии множественной миеломы у взрослых пациентов. Фармакоэкономика: теория и практика. 2018;6(4):10-19. DOI 10.30809/phe.4.2018.2Klabukova D.L., Krysanov V.S., Polyakova K.I., Ermolaeva T.N., Davydovskaya M.V., Kokushkin K.A. Economic effect of the application of three-component schemes with Iksasomib or Carfilsomib for therapy of multiple myeloma in adult patients. Pharmacoeconomics: theory and practice. 2018;6(4):10-19. (In Russ.) DOI 10.30809/phe.4.2018.2

The authors declare that there are no conflicts of interest present.